Moderna (NASDAQ:MRNA) Price Target Raised to $41.00 at The Goldman Sachs Group

Moderna (NASDAQ:MRNA) had its target price boosted by The Goldman Sachs Group from $36.00 to $41.00 in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Other equities research analysts have also issued research reports about the stock. Bank of America dropped their target price on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a report on Monday, November 10th. BMO Capital Markets raised shares of Moderna from a “market perform” rating to a “buy” rating in a research note on Monday, January 12th. UBS Group reiterated a “neutral” rating and issued a $36.00 price objective on shares of Moderna in a report on Monday. Wolfe Research restated an “underperform” rating and set a $17.00 target price on shares of Moderna in a report on Thursday, November 20th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $31.47.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $43.93 on Tuesday. The stock has a market cap of $17.16 billion, a price-to-earnings ratio of -6.04 and a beta of 1.32. The company has a 50 day simple moving average of $37.86 and a two-hundred day simple moving average of $30.04. Moderna has a 12 month low of $22.28 and a 12 month high of $55.20. The company has a current ratio of 3.29, a quick ratio of 3.22 and a debt-to-equity ratio of 0.07.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.79) by $0.68. The firm had revenue of $678.00 million for the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The firm’s quarterly revenue was down 33.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.91) earnings per share. As a group, analysts predict that Moderna will post -9.61 earnings per share for the current year.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares in the company, valued at $115,679.52. The trade was a 85.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 10.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Rothschild Investment LLC boosted its stake in shares of Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after buying an additional 446 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in Moderna in the 2nd quarter valued at approximately $26,000. Whittier Trust Co. acquired a new position in Moderna during the 2nd quarter worth approximately $28,000. MUFG Securities EMEA plc purchased a new position in shares of Moderna during the 2nd quarter worth approximately $28,000. Finally, Flagship Harbor Advisors LLC purchased a new position in shares of Moderna during the 4th quarter worth approximately $31,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.